Regeneron(REGN)
Focus: Regeneron is a large publicly-traded biotechnology company generating $13.1B in revenue, with a dominant ophthalmology franchise (EYLEA) and growing oncology/immunology pipelines. The company operates at significant R&D intensity (34%) and maintains a diverse portfolio across small molecules and biologics.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
13,000
Open Jobs
571+225 this month
Hot — 456 jobs added in 30d
Net +225 (456 new, 231 removed). Aggressive expansion phase.
Should You Work at Regeneron?
AI assessmentRegeneron offers financial stability and R&D scale, but career growth depends on pipeline execution and diversification away from EYLEA dependency.
Why Work Here
- Large-scale R&D investment ($4.4B FY2025) with 60 active R&D hires and a Phase 3 pipeline spanning oncology, immunology, and rare disease.
- Public company stability with $4.0B net income (FY2025) and $2.7B cash, providing strong job security and career continuity.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$13.1B
Key Products
$74M Part DStable
Peak
Flagship product generating 85% of company revenue; dominant ophthalmology treatment with sustained peak-stage sales.
Help build intelligence for Regeneron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.